Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again
US Appeals Court Denies Genentech Request For Injunction On Bevacizumab
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
